What is Masimo?
Founded in 1989 and headquartered in Irvine, California, Masimo Corporation is a prominent medical technology company renowned for its pioneering work in patient monitoring. Its core innovation lies in proprietary Signal Extraction Technology (SET) pulse oximetry, which revolutionized the field by providing accurate measurements even under challenging conditions such as patient motion and low perfusion. Beyond pulse oximetry, Masimo's portfolio extends to medical devices, sensors, hospital automation, connectivity solutions, and telehealth platforms, serving both hospital and home healthcare settings worldwide. The company's consistent pursuit of technological advancement positions it as a key player in enhancing patient care and safety globally.
How much funding has Masimo raised?
Masimo has raised a total of $387.9M across 3 funding rounds:
Stock Offering
$233M
Grant
$5M
Debt
$150M
Stock Issuance/Offering (2007): $233M with participation from Undisclosed
Grant (2016): $5M led by Bill & Melinda Gates Foundation
Debt (2018): $150M supported by Bank of the West and JP Morgan Chase
Key Investors in Masimo
Bill & Melinda Gates Foundation
The Bill & Melinda Gates Foundation, established in 2000, is a major philanthropic organization dedicated to improving global health and reducing poverty. Their investment in Masimo suggests a focus on technologies that can significantly impact patient care, particularly in underserved or resource-limited settings.
Bank of the West
Bank of the West is a financial institution providing a range of banking and financial services. Their participation in Masimo's funding indicates a belief in the company's financial stability and growth potential within the healthcare sector.
JP Morgan Chase
JPMorgan Chase & Co. is a global financial services firm. Their involvement in Masimo's financing highlights the company's significant scale and the strategic importance of its medical technology solutions, attracting backing from major financial players.
What's next for Masimo?
The substantial enterprise-level funding and recent strategic investment signal Masimo's intent to further accelerate its research and development initiatives, expand its global market reach, and potentially pursue strategic acquisitions. This capital infusion is likely to bolster its efforts in areas such as advanced sensor technology, hospital connectivity, and telehealth solutions, reinforcing its competitive edge in the rapidly evolving medical technology landscape. Masimo's continued focus on innovation, supported by this significant financial backing, positions it for sustained growth and leadership in improving patient outcomes.
See full Masimo company page
